By John Vandermosten, CFATSE:PMN.TO | OTC:ARFXFREAD THE FULL PMN.TO RESEARCH REPORTThird Quarter 2018 ResultsProMIS Neurosciences Inc. (TSE:PMN.TO) (OTC:ARFXF) has experienced a busy quarter since our previous report providing presentations and press releases addressing the:‣ safety profile of PMN310 with respect to BAN2401 and aducanumab;‣ the importance of selectivity against...
By Brian Marckx, CFANASDAQ:EYEG | NYSE:AGNREAD THE FULL EYEG RESEARCH REPORTQ3 Financial Results, Operating Update…EyeGate (NASDAQ:EYEG) announced Q3 financial results and provided a business update. In terms of the financials, milestone from the EGP-437 development agreement with Bausch Health Companies (BHC, formerly Valeant Pharmaceuticals) in the amount $315k was...
By Brian Marckx, CFANASDAQ:CEMIREAD THE FULL CEMI RESEARCH REPORTQ3 2018: Record YTD revenue, margins take a hit but should begin to rebound…Chembio (NASDAQ:CEMI) reported financial results for their third quarter ending September 30, 2018. Q3 made it three-for-three with us substantially underestimating product and total revenue every quarter so...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTBusiness UpdatePart 1 of Phase 2b Dose-Ranging, Efficacy Study Successfully CompletedOn November 27, 2018, Antibe Therapeutics, Inc. (TSX:ATE.V) announced that it has successfully completed the first part of the Phase 2b dose-ranging, efficacy study of ATB-346. The first part of the...
By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORTQ3 Results: Results Inline But FDA-Action vs. Competitors Could Create Short-Term Headwind. Long-Term Outlook Intact…Viveve (NASDAQ:VIVE) reported Q3 2018 financial results and provided a business update. Relative to the financials, both the top and bottom lines were a hair lower than...
By David Bautz, PhDNASDAQ:CERCREAD THE FULL CERC RESEARCH REPORTBusiness UpdateRare Pediatric Disease ProgramsOn October 31, 2018, Cerecor, Inc. (NASDAQ:CERC) announced the submission of three Orphan Drug Designation (ODD) requests for three of the development products acquired from the purchase of Ichorion Therapeutics, Inc. Each of them is being developed...
By John Vandermosten, CFAOTC:GOVXREAD THE FULL GOVX RESEARCH REPORTGeoVax Labs, Inc. (OTC:GOVX) filed their 3Q:18 10-Q and press release on November 8th providing an operational and financial update on the company’s performance. Several highlights were noted in the release, including the receipt of several grants from government entities, collaborations...
By John Vandermosten, CFANASDAQ:TENXREAD THE FULL TENX RESEARCH REPORTThird Quarter 2018 ReviewDuring the third quarter Tenax Therapeutics, Inc. (NASDAQ:TENX) continued to prepare its Phase II levosimendan trial for PH-HFpEF enrollment. Efforts in the areas of contracting, budgeting, scheduling, investigational review board approvals and site set up dominated the executive...
By John Vandermosten, CFANASDAQ:ATRSREAD THE FULL ATRS RESEARCH REPORTAntares Pharma, Inc. (NASDAQ:ATRS) reported third quarter results on November 6th posting revenue growth of 19% and achieving a quarterly sales record for the company. Earnings loss was limited to a penny. Highlights for the quarter and quarter to date include...
By John Vandermosten, CFANASDAQ:LPCNREAD THE FULL LPCN RESEARCH REPORT3Q:18 Operational and Financial ResultsLipocine (NASDAQ:LPCN) filed its 3Q:18 10-Q and posted its earnings release on November 7, 2018 reporting net loss per share of ($0.12). These results were better than our forecast due to lower R&D and G&A. Highlights for...